Open Access

Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study

  • Authors:
    • Antonio Ieni
    • Cristina Pizzimenti
    • Giuseppe Broggi
    • Rosario Caltabiano
    • Antonino Germanò
    • Giuseppe Maria Vincenzo Barbagallo
    • Paolo Vigneri
    • Giuseppe Giuffrè
    • Giovanni Tuccari
  • View Affiliations

  • Published online on: August 11, 2022     https://doi.org/10.3892/ol.2022.13456
  • Article Number: 336
  • Copyright: © Ieni et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

p62/SQSTM1/Sequestosome‑1 is an autophagic protein that serves a crucial role in cellular metabolism, proliferation and malignant growth. Notably, autophagy may influence the development and resistance to therapy of numerous types of human cancer. In the present pilot study, the immunohistochemical pattern of p62 was analyzed in a cohort of patients with isocitrate dehydrogenase (IDH)1/2 wild‑type glioblastoma (GBM), in primary and recurrent samples, in order to verify the concordance or discordance between the primary and recurrent tumors. In addition, the association between p62, and patient outcome and O6‑methylguanine‑DNA methyltransferase (MGMT) status was assessed. The results revealed p62 immunoexpression in the nucleus and cytoplasm of neoplastic elements in 45% of primary and 55% of recurrent cases of GBM. A discordant p62 immunoreactivity was detected in 35% of cases, with a variation either with positive or negative conversion of p62 status. Statistically, p62 expression and MGMT status exhibited a significant prognostic value by univariate analysis, whereas only MGMT promoter methylation status emerged as an independent prognostic factor by multivariate analysis. Finally, the most favorable prognosis was documented when the same GBM case was positively concordant for both p62 expression and MGMT methylated status. Since little data are available regarding the association between p62 expression and MGMT in GBM, further investigations may be required to determine if new targeted therapies may be addressed against autophagy‑related proteins, such as p62.
View Figures
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ieni A, Pizzimenti C, Broggi G, Caltabiano R, Germanò A, Barbagallo GM, Vigneri P, Giuffrè G and Tuccari G: Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study. Oncol Lett 24: 336, 2022
APA
Ieni, A., Pizzimenti, C., Broggi, G., Caltabiano, R., Germanò, A., Barbagallo, G.M. ... Tuccari, G. (2022). Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study. Oncology Letters, 24, 336. https://doi.org/10.3892/ol.2022.13456
MLA
Ieni, A., Pizzimenti, C., Broggi, G., Caltabiano, R., Germanò, A., Barbagallo, G. M., Vigneri, P., Giuffrè, G., Tuccari, G."Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study". Oncology Letters 24.4 (2022): 336.
Chicago
Ieni, A., Pizzimenti, C., Broggi, G., Caltabiano, R., Germanò, A., Barbagallo, G. M., Vigneri, P., Giuffrè, G., Tuccari, G."Immunoexpression of p62/SQSTM1/Sequestosome‑1 in human primary and recurrent IDH1/2 wild‑type glioblastoma: A pilot study". Oncology Letters 24, no. 4 (2022): 336. https://doi.org/10.3892/ol.2022.13456